Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

EEnlivex Ltd.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
E

Enlivex Ltd.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
    Sep 22, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the termination of a securities purchase agreement entered into with the Rain Foundation, pursuant to which the Company had agreed, subject to shareholder approval,...

  • Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
    Jul 30, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a...

  • Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
    Jul 30, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a...

  • Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
    Jul 29, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the...

  • Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
    Jul 29, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the...

  • Enlivex Announces $400,000,000 Private Placement
    Jul 28, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company"), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of...

  • Enlivex Announces $400,000,000 Private Placement
    Jul 28, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or "the Company"), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of...

  • Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
    Jul 20, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    &#8226;As of July 18, 2026, net asset value (NAV1) per share was $66.16 <td style="vertical-align: top...

  • Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
    Jul 20, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    &#8226;As of July 18, 2026, net asset value (NAV1) per share was $66.16 <td style="vertical-align: top...

  • Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra&#8482; in Age-Related Knee Osteoarthritis
    Jul 13, 2026Enlivex Therapeutics Ltd ENLV News powered by B2i Technologies - SmartWire

    FDA grant of RMAT designation to Allocetra&#8482; reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of-life and limited treatment options.RMAT designation provides the benefit of intensive, early FDA engagement and guidance for...

…
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions
$0.65Close · Sep 22, 2026